{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:31Z","timestamp":1791472111000,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory Bowel Disease (IBD) is characterized by recurrent flare-ups, significantly impairing patients\u2019 long-term quality of life and increasing the risk of complications. As the first chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-\u03b1), infliximab blocks TNF-\u03b1-mediated inflammatory cascades and has become an important therapeutic agent for moderate-to-severe IBD. Although clinical trials have highlighted its safety and efficacy, real-world data on adverse events (AEs) associated with different administration routes remains limited. This study aims to analyze the U. S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) to compare the spectrum and time-to-onset of infliximab-related AEs across different administration routes, following the READUS-PV guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the FAERS database were analyzed using discriminant and stratified analytical methods, and reporting odds ratio (ROR) methods for comparative analysis, and the Weibull distribution for the time to onset of adverse reaction events analysis. The study examined data from the first quarter of 2014 through the first quarter of 2025 to analyze adverse event signals and the time of occurrence between intravenous and subcutaneous infliximab administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 178,925 adverse reaction reports associated with infliximab were identified. Among these, 5,144 events were linked to intravenous administration, while 1,084 events were related to subcutaneous administration. The analysis revealed that infection-related adverse reactions were common with both different administration routes of infliximab. Notably, reports of infusion-related reactions were more frequently associated with intravenous administration, while delayed hypersensitivity reactions involving musculoskeletal and connective tissue disorders were more prominently reported in association with subcutaneous administration. Additionally, Weibull distribution analysis indicated a median onset time of 436.5\u202fdays for intravenous administration and 376\u202fdays for subcutaneous administration. Both routes exhibited early failure signals, suggesting a gradually decreasing risk of AEs over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AEs and the time of onset vary across different administration routes of infliximab. Consequently, clinicians should consider these differences when selecting the administration route to balance therapeutic efficacy with the risk of adverse reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1834815","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:00:27Z","timestamp":1780315227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoke","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Central People's Hospital of Zhanjiang","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minpeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Suqian First Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central People's Hospital of Zhanjiang","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central People's Hospital of Zhanjiang","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Suqian First Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","article-title":"Inflammatory bowel disease","volume":"50","author":"Bruner","year":"2023","journal-title":"Prim Care"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ueg2.12319","article-title":"Environmental risk factors for inflammatory bowel disease","volume":"10","author":"Singh","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/01.MIB.0000225338.14356.d5","article-title":"A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC","volume":"12","author":"Stucchi","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","article-title":"Study of tumor necrosis factor receptor in the inflammatory bowel disease","volume":"29","author":"Souza","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/bdd.2198","article-title":"Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling","volume":"40","author":"Kimura","year":"2019","journal-title":"Biopharm Drug Dispos"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.2010.03760.x","article-title":"Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists","volume":"71","author":"de Vries","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/ajg.2009.509","article-title":"Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas","volume":"104","author":"Ng","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.crohns.2014.01.001","article-title":"Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease","volume":"8","author":"Hukkinen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1651-2227.2010.01938.x","article-title":"Infliximab therapy in children with Crohn\u2019s disease: a one-year evaluation of efficacy comparing \u2018top-down\u2019 and \u2018step-up\u2019 strategies","volume":"100","author":"Kim","year":"2011","journal-title":"Acta Paediatr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD012623","DOI":"10.1002\/14651858.CD012623.pub2","article-title":"Infliximab for medical induction of remission in Crohn's disease","volume":"11","author":"Gordon","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.gastha.2024.11.004","article-title":"A comparison of intravenous infliximab versus subcutaneous infliximab on remission rates, safety, costs, patient preferences in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"4","author":"Nieto Dominguez","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"ref17","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-025-08876-5","article-title":"Switching to subcutaneous infliximab maintenance therapy is effective in patients with inflammatory bowel disease","volume":"70","author":"Rautakorpi","year":"2025","journal-title":"Dig Dis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther Drug Monit"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"jjaf060","DOI":"10.1093\/ecco-jcc\/jjaf060","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)","volume":"19","author":"Colombel","year":"2025","journal-title":"J Crohns Colitis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Chetwood","year":"2024","journal-title":"J Crohns Colitis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"18641","DOI":"10.1038\/s41598-025-03850-7","article-title":"Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1517616","DOI":"10.3389\/fphar.2025.1517616","article-title":"Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"20420986241303428","DOI":"10.1177\/20420986241303428","article-title":"Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Liu","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in Pharmaco Vigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","article-title":"Post-marketing safety concerns with rimegepant based on a pharmacovigilance study","volume":"25","author":"Hu","year":"2024","journal-title":"J Headache Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/S1590-8658(08)60532-0","article-title":"Minimizing infliximab toxicity in the treatment of inflammatory bowel disease","volume":"40","author":"Orlando","year":"2008","journal-title":"Dig Liver Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","first-page":"667","article-title":"Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis","volume":"29","author":"Shergy","year":"2002","journal-title":"J Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14712598.2020.1811849","article-title":"Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13","volume":"21","author":"Parigi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref34","first-page":"610","article-title":"Traitement de maladies inflammatoires: s\u00e9curit\u00e9 d\u2019emploi \u00e0 long terme de l\u2019infliximab [Treatment of inflammatory diseases: safety of long-term use of infliximab]","volume":"31","author":"Schaible","year":"2001","journal-title":"Presse Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"S-1371","DOI":"10.1016\/S0016-5085(18)34477-9","article-title":"Tu2018-Novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: Initial results from a Phase I open-label randomized controlled trial in patients with active Crohn\u2019s disease","volume":"6","author":"Schreiber","year":"2018","journal-title":"Gastroenterology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: Management of Crohn's disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1834815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:00:29Z","timestamp":1780315229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1834815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1834815"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1834815","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1834815"}}